Stevanato Group(STVN) ZACKS·2025-03-06 13:45Company Performance - Stevanato Group reported quarterly earnings of $0.20 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.19 per share a year ago [1] - The company posted revenues of $352.68 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 1.85%, and up from $345.22 million year-over-year [2] - Over the last four quarters, Stevanato has not surpassed consensus EPS estimates, but has topped consensus revenue estimates three times [2] Stock Outlook - Stevanato shares have declined approximately 12.5% since the beginning of the year, contrasting with the S&P 500's decline of 0.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $0.12 on revenues of $260.58 million, and for the current fiscal year, it is $0.58 on revenues of $1.25 billion [7] Industry Context - The Medical - Drugs industry, to which Stevanato belongs, is currently ranked in the bottom 46% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment [5] - Another company in the same industry, Durect, is expected to report a quarterly loss of $0.02 per share, with revenues projected to be $6.91 million, reflecting a significant year-over-year increase [9]